Targeting adenosine A2A receptor antagonism for treatment of cancer

被引：47

作者：

Congreve, Miles ^{[1
]}

Brown, Giles A. ^{[1
]}

Borodovsky, Alexandra ^{[2
]}

Lamb, Michelle L. ^{[3
]}

机构：

[1] Heptares Therapeut Ltd, Granta Pk, Steinmetz Bldg, Cambridge, England

[2] AstraZeneca, IMED Biotech Unit, Biosci Oncol, Boston, MA USA

[3] AstraZeneca, IMED Biotech Unit, Med Chem Oncol, Boston, MA USA

来源：

EXPERT OPINION ON DRUG DISCOVERY | 2018年 / 13卷 / 11期

关键词：

G protein-coupled receptor; GPCR; adenosine receptors; A(2A)R; structure-based drug design; SBDD; immune-oncology; PROTEIN-COUPLED RECEPTORS; CRYSTAL-STRUCTURE; T-CELL; LIGAND-BINDING; DRUG DESIGN; CD73; EXPRESSION; INHIBITION; DISCOVERY; GPCRS;

D O I：

10.1080/17460441.2018.1534825

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: Adenosine A(2A) Receptor (A(2A)R) antagonists are an emerging class of agents that treat cancers, both as a monotherapy and in combination with other therapeutic agents. Several studies support the accumulation of extracellular adenosine in the tumor microenvironment as a critical mechanism in immune evasion implicating A(2A)R antagonists for use in immuno-oncology. Areas covered: In this perspective article, the authors briefly outline the history of the A(2A)R antagonist field for central nervous system indications and give their perspective on the status of agents progressing today in oncology. A brief description of the biological rationale in oncology is given. A particular focus of this article is progress in A(2A)R structure determination and its impact on Structure-Based Drug Design. Expert opinion: Our understanding of the A(2A)R antagonist mechanism of action has changed and is now being clinically validated by several key companies in the oncology field. This area is likely to rapidly develop over the next 1-2 years.

引用

页码：997 / 1003

页数：7

共 104 条

[31]

Emens L, 2017, AM ASS CANC RES AACR

[32]

Fons P, 2018, CANC RES S, V78

[33] Adenosine A2A Receptor Antagonists in Neurodegenerative Diseases: Huge Potential and Huge Challenges [J].

Franco, Rafael ;

Navarro, Gemma .

FRONTIERS IN PSYCHIATRY, 2018, 9

[34] Nanodiscs for INPHARMA NMR Characterization of GPCRs: Ligand Binding to the Human A2A Adenosine Receptor [J].

Fredriksson, Kai ;

Lottmann, Philip ;

Hinz, Sonja ;

Onila, Iounut ;

Shymanets, Aliaksei ;

Harteneck, Christian ;

Mueller, Christa E. ;

Griesinger, Christian ;

Exner, Thomas E. .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (21) :5750-5754

[35]

Galezowski M, 2018, CANC RES S, V78

[36] Cryo-EM structure of the adenosine A2A receptor coupled to an engineered heterotrimeric G protein [J].

Garcia-Nafria, Javier ;

Lee, Yang ;

Bai, Xiaochen ;

Carpenter, Byron ;

Tate, Christopher G. .

ELIFE, 2018, 7

[37] Regadenoson [J].

Garnock-Jones, Karly P. ;

Curran, Monique P. .

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2010, 10 (01) :65-71

[38] Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration [J].

Gomes, Catarina V. ;

Kaster, Manuella P. ;

Tome, Angelo R. ;

Agostinho, Paula M. ;

Cunha, Rodrigo A. .

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2011, 1808 (05) :1380-1399

[39] Targeting CD73 in the tumor microenvironment with MEDI9447 [J].

Hay, Carl M. ;

Sult, Erin ;

Huang, Qihui ;

Mulgrew, Kathy ;

Fuhrmann, Stacy R. ;

McGlinchey, Kelly A. ;

Hammond, Scott A. ;

Rothstein, Raymond ;

Rios-Doria, Jonathan ;

Poon, Edmund ;

Holoweckyj, Nick ;

Durham, Nicholas M. ;

Leow, Ching Ching ;

Diedrich, Gundo ;

Damschroder, Melissa ;

Herbst, Ronald ;

Hollingsworth, Robert E. ;

Sachsenmeier, Kris F. .

ONCOIMMUNOLOGY, 2016, 5 (08)

[40] Hydration Site Thermodynamics Explain SARs for Triazolylpurines Analogues Binding to the A2A Receptor [J].

Higgs, Christopher ;

Beuming, Thijs ;

Sherman, Woody .

ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (04) :160-164

← 1 2 3 4 5 6 7 8 9 10 →